Galectin Therapeutics Inc (GALT) stock
Close on Nov 11, 2026Market cap $331.80MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $331.80M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$27.84M
- EPS, diluted
- -$0.44
- Book value per share
- -$2.10
- Diluted shares
- 66M
Trading
- Next earnings
- Nov 13, 2026 (estimated, before the open)
- Previous close
- $3.38
- Open
- $3.38
- Day's range
- $3.29 – $3.41
- Volume
- 77,983
- Average volume (20 days)
- 191,366
- Index membership
- Russell 2000 (since Jun 2026)
- Beta (5 years)
- 0.67
- 52-week range
- $2.02 – $7.13
- RSI (14 days)
- 45.2
- Volatility (1 year)
- 91.7%
- Relative volume
- 0.23×
- WACC
- 8.2%
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | GALT | S&P 500 | Difference | GALT per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -16.5% | -2.4% | −14.1 pts | ||
| 3 months | +5.1% | -1.2% | +6.3 pts | ||
| Year to date | -20.9% | +12.3% | −33.2 pts | ||
| 1 year | -40.2% | +12.4% | −52.6 pts | ||
| 3 years | +56.7% | +78.8% | −22.1 pts | +16.1% | +21.4% |
| 5 years | +14.2% | +75.2% | −60.9 pts | +2.7% | +11.9% |
| 10 years | +261.5% | +311.1% | −49.6 pts | +13.7% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Galectin Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Results
- Results
- Update
- Results
About Galectin Therapeutics
Pharmaceutical Preparations
Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on researching and developing therapies for fibrotic conditions and cancers. The company utilizes plant-derived complex carbohydrates to create compounds that inhibit galectin proteins, particularly galectin-3. Its lead drug candidate is belapectin, which is evaluated for treating metabolic dysfunction-associated steatohepatitis with cirrhosis and portal hypertension, as well as head and neck cancers. Additionally, the company develops orally administered small-molecule inhibitors through a joint venture subsidiary. Because all drug candidates remain in clinical or preclinical development, the firm has no commercial customers and directs its therapies toward patients suffering from chronic liver disease and life-threatening malignancies.
Company profile, executives and historyGalectin Therapeutics stock: common questions
What is Galectin Therapeutics's stock price?
GALT closed at $3.29 on Nov 11, 2026, down 2.66% on the day. Over the past 52 weeks it traded between $2.02 and $7.13.
What is Galectin Therapeutics's market cap?
Galectin Therapeutics was worth $331.80M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is GALT's P/E ratio?
Galectin Therapeutics lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.44), so it has no meaningful P/E ratio.
Does Galectin Therapeutics pay a dividend?
No. Galectin Therapeutics has not paid a cash dividend over the last twelve months.
When does Galectin Therapeutics report earnings next?
Galectin Therapeutics is expected to report Q3 FY2026 results on Nov 13, 2026, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has GALT stock performed over the past year?
Including dividends, GALT returned -40.2% over the past year, against +12.4% for the S&P 500.
How many GALT shares are sold short?
9M shares were sold short at the latest FINRA report, 24.46% of the float, or 46.3 days of average trading volume.
Who are Galectin Therapeutics's competitors?
Companies most similar to Galectin Therapeutics by business, industry and size include CLRB, NXTC, ALT, CRBP, LRMR.
See a number that looks wrong?